DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
Greg was also central to the planning, design, and construction of this facility
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
FDA has concluded that this inspection is 'closed'
A significant proportion of healthcare professionals still tend to favor branded drugs
The facility will manufacture tablets, capsules, and injections for the oncology segment
Pharma Solutions operates 10 research and development and/or production sites globally
Subscribe To Our Newsletter & Stay Updated
